Does MMF really slow down fibrosis of HCV recurrence in liver transplant recipients?

被引：1
|
作者：
Germani, Giacomo [1 ,2 ]
Tsochatzis, Emmanuel [1 ]
Burroughs, Andrew Kenneth [1 ]
机构：
[1] Royal Free Sheila Sherlock Liver Ctr & Univ, Royal Free Hosp, Dept Surg, London, England
[2] Padua Univ Hosp, Dept Surg & Gastroenterol Sci, Padua, Italy
来源：
TRANSPLANT INTERNATIONAL | 2011年 / 24卷 / 09期
关键词：
HEPATITIS-C; MYCOPHENOLATE-MOFETIL; AZATHIOPRINE; IMPACT;
D O I：
10.1111/j.1432-2277.2011.01288.x
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：E77 / E78
页数：2
相关论文
共 50 条
  • [41] PROSPECTIVE VALIDATION OF A NON-INVASIVE INDEX FOR PREDICTING LIVER FIBROSIS IN HCV-INFECTED LIVER TRANSPLANT RECIPIENTS
    Benlloch, Salvador
    Berenguer, Marina
    Aguilera, Victoria
    Barquero, Claudia
    Heredia, Laura
    Rayon, Jose
    Prieto, Martin
    HEPATOLOGY, 2009, 50 (04) : 558A - 558A
  • [42] Optimal dosing of mycophenolate mofetil (MMF) is necessary to delay hepatitis C recurrence (HEP CR) in liver transplant recipients.
    Fasola, CG
    Netto, GJ
    Christensen, LL
    Sanchez, EQ
    Molmenti, EM
    Gonwa, TA
    Goldstein, RM
    Levy, MF
    Klintmalm, GB
    HEPATOLOGY, 2001, 34 (04) : 639A - 639A
  • [43] Natural history of recurrence of hepatitis C (HEP CR) in liver transplant recipients (OLT) under mycophenolate mofetil (MMF) immunosuppression (IS).
    Fasola, CG
    Netto, GJ
    Christensen, LL
    Molmenti, EP
    Gonwa, TA
    Goldstein, RM
    Levy, MF
    Klintmalm, GB
    HEPATOLOGY, 2001, 34 (04) : 639A - 639A
  • [44] HCV treatment with DAA in patients listed for liver transplant does not result in an increased risk of HCC recurrence post-liver transplant
    Mazzarelli, C.
    Invernizzi, F.
    Suddle, A.
    Donato, M. F.
    Belli, L. S.
    Cannon, M. D.
    Marenco, S.
    Angrisani, D.
    Iavarone, M.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S117 - S118
  • [45] Does Time Really Slow Down during a Frightening Event?
    Stetson, Chess
    Fiesta, Matthew P.
    Eagleman, David M.
    PLOS ONE, 2007, 2 (12):
  • [46] Pharmacokinetics of Mycophenolate Mofetil in Pediatric Liver Transplant Recipients to Optimize MMF Dose
    Barau, C.
    Habes, D.
    Debray, D.
    Taburet, A. M.
    Furlan, V.
    THERAPEUTIC DRUG MONITORING, 2009, 31 (05) : 651 - 652
  • [47] Slow response to antiviral therapy in liver transplant recipients
    Khubutia, M.
    Salienko, A.
    Syutkin, V.
    Chulanov, V.
    Karandashova, I.
    Dolgin, V.
    Novruzbekov, M.
    JOURNAL OF VIRAL HEPATITIS, 2014, 21 : 45 - 46
  • [48] Immunological Factors and Liver Fibrosis in Pediatric Liver Transplant Recipients
    Markiewicz-Kijewska, Malgorzata
    Kalicinski, Piotr
    Kluge, Przemyslaw
    Piatosa, Barbara
    Jankowska, Irena
    Rekawek, Aneta
    Kostecka, Ewa
    Kurowski, Przemyslaw N.
    ANNALS OF TRANSPLANTATION, 2015, 20 : 279 - 284
  • [49] Incidence and recurrence of autoimmune hepatitis in liver transplant recipients
    Molmenti, EP
    Netto, GJ
    Crippin, JS
    Conkey, AC
    Hoover, TC
    Jennings, LW
    Jung, GJ
    Levy, MF
    Goldstein, RM
    Gonwa, TA
    Klintmalm, GS
    TRANSPLANTATION, 1999, 67 (09) : S578 - S578
  • [50] Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence
    Tisone, G
    Orlando, G
    Cardillo, A
    Palmieri, G
    Manzia, TM
    Baiocchi, L
    Lionetti, R
    Anselmo, A
    Toti, L
    Angelico, M
    JOURNAL OF HEPATOLOGY, 2006, 44 (04) : 702 - 709
12345